Diabetes Management

One of the priority fields in order to use local capacities for transferring technologies and local manufacturing is medical care of non-communicable diseases. Since the number of patients with non- communicable diseases is high, and mostly are diabetes and hypertensive patients, also considering prioritize of UK Medical Equipment Department under UK Ministry of Health authority. Localizes diagnostic and drug delivery products related to diabetes management such as SMBG and Insulin delivery system and hypertension management such as BPMS. GISP’s Production infrastructures in 1st and 2nd today are active and available for operation.

Hypertension Management

Effective management and treatment of hypertension requires clinicians and patients to work together to balance pharmacologic and nonpharmacologic interventions and prevent target organ damage.

The 2016 American Diabetes Association's (ADA's) standards of medical care in diabetes indicate that a majority of patients with diabetes mellitus have hypertension. In patients with type 1 diabetes, nephropathy is often the cause of hypertension, whereas in type 2 diabetes, hypertension is one of a group of related cardiometabolic factors. Hypertension remains one of the most common causes of congestive heart failure (CHF). Antihypertensive therapy has been demonstrated to significantly reduce the risk of death from stroke and coronary artery disease.

Other studies have demonstrated that a reduction in blood pressure (BP) may result in improved renal function. Therefore, earlier detection of hypertensive nephrosclerosis (using means to detect microalbuminuria) and aggressive therapeutic interventions (particularly with angiotensin-converting enzyme inhibitor drugs [ACEIs]) may prevent progression to end-stage renal disease.